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The purpose of the study was to analyse the needs of women who participated in a routine follow-up programme after treatment for
primary breast cancer. A cross-sectional survey was conducted using a postal questionnaire among women without any sign of
relapse during the routine follow-up period. The questionnaire was sent 2–4 years after primary surgical treatment. Most important
to patients was information on long-term effects of treatment and prognosis, discussion of prevention of breast cancer and hereditary
factors and changes in the untreated breast. Patients preferred additional investigations (such as X-ray and blood tests) to be part of
routine follow-up visits. Less satisfaction with interpersonal aspects and higher scores on the Hospital Anxiety and Depression Scale
(HADS) scale were related to stronger preferences for additional investigation. Receiving adjuvant hormonal or radiotherapy was
related to a preference for a more intensive follow-up schedule. There were no significant differences between patients treated with
mastectomy compared to treated with breast-conserving therapy. During routine follow-up after a diagnosis of breast cancer, not all
patients needed all types of information. When introducing alternative follow-up schedules, individual patients’ information needs and
preferences should be identified early and incorporated into the follow-up routine care, to target resources and maximise the
likelihood that positive patient outcomes will result.
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Routine follow-up programmes in specialist clinics are part of the
standard medical care after treatment for primary breast cancer.
Regularly scheduled follow-up visits are intended to detect and
treat recurrence at an early stage and provide reassurance and
psychological support to the patient (Tomiak and Piccart, 1993).
There is much debate about how to organise cost-effective routine
follow-up (Dewar, 1995). In current follow-up schedules in
Western countries, patients are seen for follow-up about 12–17
times in the first 5 years after surgery for breast cancer (Schapira
and Urban, 1991). These follow-up visits are time consuming and
expensive for both the patient and the physician. Moreover, the
effect of follow-up on overall survival rates remains highly
questionable (GIVIO Investigators, 1994; Palli et al, 1999; te
Boekhorst et al, 2001; Jacobs et al, 2001).
Given these considerations, alternative strategies in follow-up
have been proposed, including the introduction of specialised
breast-care nurses to perform the follow-up (Bryan et al, 2002),
primary care involvement (Grunfeld et al, 1996), various forms of
patient-initiated follow-up (Brown et al, 2002), and less-intensive
and shorter follow-up schedules (Gulliford et al, 1997). A patient’s
perspective is an important factor in evaluating these various
follow-up strategies.
In this paper, we focus on a patient’s needs and preferences in
routine follow-up 2–4 years after treatment for primary breast
cancer. We studied the information needs and preferences
regarding additional investigations and organisation of follow-up
care. Furthermore, we analysed whether women with lower or
higher information needs could be characterised in terms of
attitudes towards and expected benefits from follow-up, psycho-
logical functioning, age, treatment for breast cancer, or duration of
follow-up.
METHODS
Participants and follow-up schedule
This cross-sectional survey was performed in December 2001
among all 116 patients who were treated for early breast cancer
between January 1998 and December 1999 in the Leiden University
Medical Center in Leiden, the Netherlands. Patients had been
treated by mastectomy or breast-conserving therapy (lumpectomy
and postoperative irradiation) and had no signs of local, regional
or distant relapse during the follow-up period. Adjuvant systemic
treatment had been given according to national guidelines. Family
risk assessment was a regular part of primary counselling and if
applicable, patients were referred to the Department of Clinical
Genetics. Such a referral did not alter the follow-up scheme
regarding breast cancer.
During primary treatment (including adjuvant treatment),
patients were informed verbally by their hospital doctor about
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lthe benefits and complications of therapies. Information on the
goals of follow-up and on the investigations performed was
not given in a structured way and there was no written information
on these topics. In that time period, in our hospital there was
no counselling or support of a specialist breast-care nurse
available.
All patients participated in a standard routine follow-up
schedule according to Dutch Association of Comprehensive
Cancer Centers guidelines for follow-up (Vademecum Oncologie,
1992). This included visits every 3 months during the first 2 years,
visits every 6 months during the next 3 years, and annual visits
thereafter, for a maximum of 10 years. Follow-up visits were
performed by a hospital doctor in the surgical oncology outpatient
clinic. Patients treated by radiation or chemotherapy were also
seen in the radiation or medical oncology clinic. As a consequence,
patients were reviewed by several physicians during their follow-
up. During each visit, a history was taken concerning symptoms
that could signal relapse or metastases, and a standard physical
examination was performed. Mammography was carried out at
yearly intervals.
A final questionnaire was mailed to the home of all patients
(n¼116) accompanied with a letter that explained the purpose of
the study. The questionnaire could be sent back in a self-addressed
envelope. Initially, 63 patients returned the questionnaire. A total
of 53 patients were sent a reminder, resulting in an additional 21
questionnaires returned. In total, 84 questionnaires were returned
(response rate 72%). The nonresponders did not differ regarding
age or received treatment (P¼0.49).
Measurements
Apart from general data concerning sociodemographic status and
medical history, the postal questionnaire consisted of six sections
that are outlined below. The ‘Expected benefits from routine follow-
up’ and ‘Needs and preferences in routine follow-up’ were
measured with a self-developed questionnaire, because existing
questionnaires (Degner et al, 1997; Graydon et al, 1997; Mesters
et al, 2001) were unsuitable for measuring specific needs and
benefits in breast cancer routine follow-up. In a pilot study, the
feasibility of the questionnaire was tested, for acceptability and
understanding, among 15 women who were in follow-up at our
breast clinic and who were treated for invasive breast cancer before
January 1998.
Attitudes towards follow-up Patients were asked to fill out a
validated 15-item questionnaire on attitudes towards follow-up
that had been used to evaluate the follow-up of colorectal cancer
(Stiggelbout et al, 1997). This questionnaire consists of four
subscales: communication (with the physician), reassurance,
nervous anticipation, and specific perceived disadvantages of
follow-up. For the communication and the reassurance scales, a
higher score meant a more positive evaluation (range: 0–100). For
the nervous anticipation and the disadvantages scales, a higher
score meant more negative effects (range: 0–100).
Expected benefits from follow-up Questions were included about
the expected benefits, from a patient’s perspective, regarding the
purposes of breast self-examination, physical examination of the
breasts by a doctor, mammography, and the patient’s ideas about
the curability of the disease after the detection of distant
metastases (eight items in total). Patients could choose from four
answering categories: not at all, somewhat, rather, very much.
Scores were summed up and normalised to a 100-point scale
(transformed score¼((sum score–potential minimum of sum
scores)/potential range of sum scores) 100). A higher score
meant more expected benefits (range: 0–100). The reliability
(internal consistency) of the expected benefits from follow-up scale
was high (0.79).
Satisfaction with oncological care Patient satisfaction with
oncological care was assessed using the Dutch version of Ware’s
Patient Satisfaction Questionnaire III (PSQ III) (Hagedoorn et al,
2003). This questionnaire (36 items) was designed to measure
technical competence, interpersonal manner, and access to care.
To get an impression of the general satisfaction, we also calculated
an overall score on the PSQ III. Higher score means more
satisfaction with the oncological care received (range: 0–100).
Quality of life and psychological functioning A three-item scale
assessed fear of recurrence. This scale has been used in several
former studies at our hospital (Stiggelbout et al, 1997). The higher
the score, the more the fear of recurrence (range: 0–100). The
patients rated their overall quality of life during the preceding
week in two ways, by means of a seven-point verbal scale (ranging
from excellent to very bad (de Haes et al, 1990a); and by means of
a visual analogue scale (a 100mm horizontal line, anchored at the
extremes by ‘best imaginable quality of life’ and ‘worst imaginable
quality of life’ (de Haes et al, 1990b). Additionally, patients were
asked to fill out the Dutch version of the HADS (Spinhoven et al,
1997). The higher the score, the more anxious and depressed the
patient (range: 0–14).
Sociodemographic data and medical history Registered was age at
the time of filling in the questionnaire, stage of breast cancer
(DCIS, I, IIA, IIB, or IIIA), treatment for breast cancer
(mastectomy vs breast-conserving therapy; adjuvant hormonal
therapy (yes or no), adjuvant chemotherapy (yes or no), adjuvant
radiotherapy (yes or no)), and duration of follow-up (the period
between operation and last follow-up visit).
Needs and preferences in routine follow-up Needs of patients
were subdivided into two main categories, the first addressing
information needs, the second medical technical preferences with
respect to follow-up. The topics are outlined in Table 2. They could
chose between three answering categories: not important/do not
wish this, not very important/do not care, very important/I
certainly want this. In a factor analysis, two (orthogonal) factors or
subscales were found: a factor containing needs for general topics
and a factor containing needs for more specific topics. The
reliability (internal consistency) of the first scale, containing needs
on general topics, was 0.81 and of the second scale, containing
needs on more specific topics, was 0.91. The explained variance
was 27 and 15%, respectively. Per scale the scores were added up.
The higher the score, the more needs there were.
With respect to medical technical aspects of follow-up, patients
were asked how much they would like additional investigations
(e.g. X-ray and blood tests) to be part of the follow-up-visit, how
often they preferred to attend routine control visits (every 3
months, every 6 months, or every year), for how long they
preferred to attend routine control visits (5 years, 10 years, or
lifelong) and by whom the follow-up should be performed (general
practitioner, specialised breast-care nurse, or hospital doctor).
These four questions regarding preferences for additional in-
vestigations and organisation of routine follow-up care were
considered separately.
Analyses
The following patient characteristics were considered as possible
determinants of needs and preferences: age, treatment for breast
cancer, duration of follow-up, attitudes and expected benefits from
follow-up, satisfaction with oncological care, quality of life and
psychosocial functioning. Cutoffs for the Hospital Anxiety and
Depression Scale (HADS) were based on Carroll et al (1993) For all
scales, missing data were replaced by the individual mean for that
scale, if no more than 50% of the items on the scale were missing.
Otherwise, the scale value was considered as missing.
Needs and preferences in follow-up
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Spearman’s rank correlations, between needs and preferences on
the one hand and the patient characteristics on the other, were
calculated. For some (dicho- and trichotomous) variables, other
methods (such as w
2) would have been more appropriate. However,
these other methods rendered almost identical results and are
therefore not reported. Finally, for the patient characteristics that
correlated significantly with their needs or preferences, a multi-
variate model was constructed for each dependent variable.
RESULTS
Participants
For an overview of the patient characteristics, see Table 1. The
median age of patients was 56 years (range 33–90). The median
duration of follow-up was 3.0 years (range 2.0–4.1).
Attitudes towards follow-up Regarding the attitudes towards
follow-up, patients considered communication with the physician
as rather positive (median score: 75) and obtained a moderate
sense of reassurance from follow-up (median score: 50). They did
not perceive the disadvantages to be large, nor did they indicate
feeling much nervous anticipation (median scores: 11 and 17,
respectively).
Expected benefits from follow-up Patients had high-expected
benefits from follow-up, especially from mammography and early
detection of a breast cancer recurrence. Most patients (88%)
believed that early detection of distant metastases would
contribute to cure. Breast self-examination as an instrument of
early detection of breast cancer was not highly valued.
Satisfaction with oncological care Patients were rather satisfied
with the care they received (median score: 74). They were most
satisfied with interpersonal aspects (interpersonal manner and
Table 1 Patient characteristics (n¼84)
Age: median (range) 56 (33–90)
Stage of breast cancer
DCIS 11 (13%)
I 36 (43%)
IIA 17 (20%)
IIB 17 (20%)
IIIA 3 (4%)
Surgical therapy; n (%)
Breast-conserving therapy 32 (39 %)
With adjuvant hormonal therapy 4 (12%)
With adjuvant chemotherapy 6 (19%)
With adjuvant radiotherapy 31 (97%)
Mastectomy 51 (61 %)
With adjuvant hormonal therapy 14 (27 %)
With adjuvant chemotherapy 23 (45 %)
With adjuvant radiotherapy 15 (29 %)
Time since primary surgical therapy in years: median (range) 3.0 (2.0–4.1)
Duration of follow-up in years: median (range) 3.0 (2.0–4.1)
Attitudes towards follow-up; median (range)
Communication (with the physician) 75 (0–100)
Reassurance 50 (0–67)
Nervous anticipation 17 (0–92)
Specific perceived disadvantages of follow-up 11 (0–67)
Expected benefits from follow-up Not at all/somewhat Rather/very much
To what extent you think that y 31% 69%
Physical examination will detect a new tumour in the other breast? 13% 87%
Mammography will detect a new tumour in the other breast? 50% 50%
Self-examination will detect a new tumour in your breast?
Early detection of a new tumour in the other breast will contribute to your cure? 9 % 91%
Early detection of distant recurrences will contribute to your cure? 12% 88%
Physical examination will detect a new tumour in the operated breast? 17% 83%
Mammography will detect a new tumour in the operated breast? 10% 90%
Early detection of a tumour in the operated breast will contribute to your cure? 10% 90%
Ware’s Patient Satisfaction Questionnaire III: mean; s.e. (range)
Technical competence 73; 1.8 (35–100)
Interpersonal aspects 76; 1.9 (39–100)
Access to care 70; 1.8 (19–100)
Total score 74; 1.6 (42–100)
Quality of life and psychological functioning
Fear of recurrence; median (range) 33 (0–100)
Quality of life on a visual analogue scale; median (range) 80 (0–100)
Quality of life on a verbal scale; median (range) 5 (1–7)
HADS-anxiety; mean; s.e. (range) 5.0; 0.3 (0–13)
HADS-depression; mean; s.e. (range) 2.7; 0.3 (0–14)
Needs and preferences in follow-up
GH de Bock et al
1146
British Journal of Cancer (2004) 90(6), 1144–1150 & 2004 Cancer Research UK
C
l
i
n
i
c
a
ltime spent with physician; median score: 76). Satisfaction
regarding access to care was somewhat lower (median score: 70).
Quality of life and psychological functioning Patients had a
moderate fear of recurrence (median score: 33). They scored their
quality of life well on a visual analogue scale and on a verbal scale
(median score: 80 and 5,respectively). The mean scores on the
HADS were 5.0 for anxiety, and 2.7 for depression. Using the
previous mentioned cutoff score of 8 for the anxiety and
depression subscales, we found that 18% of this population would
warrant further psychiatric evaluation. A total of 7% had scores 11
or more and would be those most likely to have had anxiety (6%)
or depressive (4%) disorders based on DSM-IV criteria.
Regarding the patient characteristics mentioned in Table 1,
there were no statistically significant differences between patients
who were treated by means of mastectomy as compared to breast-
conserving therapy (results not shown).
Needs and preferences
Information on long-term effects and side effects of treatment and
prognosis were considered as very important (Table 2). Patients
preferred additional investigations (like X-ray and blood tests) to
be part of routine follow-up visits. Regarding more specific topics,
being able to discuss prevention of breast cancer, hereditary
factors, and changes in the untreated breast were considered as
very important by most patients. More than half of the patients
preferred lifetime follow-up, twice a year, performed by a hospital
doctor.
Determinants of needs and preferences
Higher information needs were associated with: receiving adjuvant
hormonal therapy or chemotherapy, feeling more nervous
anticipation, perceiving more disadvantages of follow-up, more
fear of recurrence, and with higher scores on the HADS-anxiety or
HADS-depression scales (Table 3). Lower informational needs
were related to higher age, higher quality of life score, and more
satisfaction with interpersonal aspects (interpersonal manner and
time spent with physician).
Women with higher scores on the HADS-anxiety or HADS-
depression scales had a stronger preference for additional
investigations (such as X-ray and blood tests) to be part of routine
follow-up visits. Women receiving adjuvant hormonal therapy and
adjuvant radiotherapy and women with a higher fear of recurrence
preferred a more intensive routine follow-up schedule. A greater
sense of reassurance from follow-up and less perceived disadvan-
tages related to follow-up were connected to a more frequent
preference for a hospital doctor as follow-up provider. Women
who had had breast-conserving therapy and women who had had
adjuvant radiotherapy more often preferred a hospital doctor as
follow-up provider.
Table 2 Needs and preferences during the follow-up visits (%)
Not important/do not
want this (%)
Not very important/do
not care (%)
Very important/I
certainly want this (%)
General topics
How much would you like the following topics to be part of the follow-up visit?
Information on the long-term effects of treatment 2.5 13.50 84.00
Information on own prognosis 6.3 8.9 84.80
Information on life rules after a diagnosis of breast cancer (e.g. nutrition) 7.5 26.30 66.30
Information on side effects of treatment 3.7 9.9 86.40
Additional investigations (e.g. X-ray and blood tests) 6.6 11.80 81.60
Specific topics
In how far you would like to talk about the following subjects during the follow-up visits?
Prevention of breast cancer 13.20 14.50 72.40
Heredity factors 18.40 13.20 68.40
Changes in the untreated breast 20.20 14.90 64.90
Feeling fatigued 25.00 22.40 52.60
Pain (e.g. nerve pain) 26.00 27.40 46.60
Fear 38.20 21.10 40.70
Nutrition 37.80 35.10 27.10
Use of OACs or HRTs
a 39.10 11.60 49.30
Breast reconstruction (if applicable) 50.00 24.20 25.80
Acceptation by family and friends 52.80 27.80 19.40
How much you would like the following topics to be part of the follow-up visit?
Information on breast cancer self-help groups 40.50 40.50 19.00
Consultation with psychologist or psychiatrist 53.80 38.50 7.7
Consultation with hospital social worker 44.30 39.20 16.50
Consultation with pastoral care provider 59.00 34.60 6.4
Organisation Every year (%) Every 6 months (%) Every 3 months (%)
How often would you prefer to attend routine control visits? 16.20 58.80 25.00
5 years (%) 10 years (%) Lifelong (%)
For how long would you prefer to attend routine control visits? 12.10 22.00 65.90
General practitioner (%) Specialised nurse (%) Hospital doctor (%)
By whom should the follow-up be performed? 7.60 6.30 86.10
aOA¼oral anticonceptiva; HRT¼hormone replacement therapy.
Needs and preferences in follow-up
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lIn multivariate analyses, satisfaction with interpersonal aspects
(interpersonal manner and time spent with physician), the score
on the HADS-anxiety scale, the adjuvant hormonal or radio-
therapy, and the perceived disadvantages remained as independent
predictors of needs and preferences (Table 4).
DISCUSSION
We analysed which needs there were regarding information and
preferences for additional investigations and organisation of
follow-up care, among women who participated in a routine
Table 3 Determinants of needs and preferences (Spearman’s rho)
General
topics
Specific
topics
Preference for
additional
investigations
Preferred follow-up
frequency
Preferred
follow-up time
Preferred
follow-up provider
Age  0.35
**  0.32
**  0.16  0.19  0.1 0.01
Stage of breast cancer 0.05 0.18 0.16  0.05 0.04 0.17
Therapy 0.07  0.14  0.3  0.14  0.16  0.23
*
Adjuvant hormonal therapy 0.24
* 0.21 0.17 0.23
* 0.05 0.04
Adjuvant chemotherapy 0.25
* 0.23
* 0.13 0.18  0.07  0.01
Adjuvant radiotherapy  0.06 0.22 0.13 0.29
** 0.06 0.23
*
Duration of follow-up in years  0.05  0.06 0.05  0.14 0.13  0.06
Attitudes towards follow-up
Communication (with the physician)  0.1  0.03  0.2 0.08  0.01 0.15
Reassurance  0.2 0.02  0.14 0.03 0.21 0.30
**
Nervous anticipation  0.07 0.25
* 0.10  0.02 0.13  0.04
Specific perceived disadvantages of follow-up 0.10 0.31
* 0.15  0.15  0.12  0.47
**
Expected benefits from follow-up  0.01 0.01  0.02 0.18 0.04 0.04
Ware’s Patient Satisfaction Questionnaire III
Technical competence  0.03  0.05  0.15  0.16  0.06 0.03
Interpersonal aspects  0.18  0.26
*  0.17  0.08 0.02 0.12
Access to care  0.04  0.18  0.14  0.05  0.06 0.18
Total score  0.12  0.17  0.16  0.08  0.03 0.15
Quality of life and psychological functioning
Fear of recurrence  0.05 0.26
* 0.21 0.30
** 0.15 0.19
Quality of life on a visual analogue scale  0.26
*  0.18  0.11  0.08 0.07  0.05
Quality of life on a verbal scale  0.05  0.28
*  0.14  0.15  0.07  0.06
HADS-anxiety 0.08 0.52
*** 0.23
* 0.14 0.14 0.04
HADS-depression  0.18 0.29
* 0.24
* 0.17 0.04 0.06
*Po0.05, **Po0.01, ***Po0.0001.
Table 4 Determinants of needs and preferences (multivariate analyses, b0s)
a
General
topics
Specific
topics
Preference
for additional
investigations
Preferred follow-up
frequency
Preferred follow-up
provider
Age  0.22  0.19 n.i. n.i. n.i.
Therapy n.i. n.i. n.i. n.i.  0.16
Adjuvant hormonal therapy 0.14 n.i. n.i 0.23
* n.i.
Adjuvant chemotherapy  0.01 .0.13 n.i. n.i. n.i.
Adjuvant radiotherapy n.i. n.i. n.i. 0.25
* 0.28
Attitudes towards follow-up
Reassurance n.i. n.i. n.i. n.i. 0.04
Nervous anticipation n.i. 0.08 n.i. n.i. n.i.
Specific perceived disadvantages of follow-up 0.01 n.i. n.i.  0.33
**
Ware’s Patients Satisfaction Questionnaire III
Interpersonal aspects n.i.  0.22
* n.i. n.i. n.i.
Quality of life and psychological functioning
Fear of recurrence n.i. 0.07 n.i. 0.13 n.i.
Quality of life on a visual analogue scale  0.13 n.i. n.i. n.i. n.i.
Quality of life on a verbal scale n.i.  0.2 n.i. n.i. n.i.
HADS-anxiety n.i. 0.38
** 0.14 n.i. n.i.
HADS-depression n.i.  0.21 0.12 n.i. n.i.
*Po0.05, **Po0.01.
an.i.¼variable not included in the multivariate model.
Needs and preferences in follow-up
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lfollow-up programme after treatment for primary breast cancer.
Information on long-term effects and side effects of treatment and
prognosis was considered very important, as well as discussing
prevention of breast cancer, hereditary factors, and changes in the
untreated breast. Patients preferred additional investigations (like
X-ray and blood tests) to be part of routine follow-up visits. More
than half of the patients preferred lifetime follow-up, twice a year
and performed by a hospital doctor. That patients preferred
additional investigations (like X-ray and blood tests) to be part of
routine follow-up visits has also been reported in other studies
(Muss et al, 1991). Related to this, more than half of the patients in
our study preferred lifetime follow-up and have high expectations
from follow-up. Most patients (88%) think that early detection of
distant recurrences will contribute to their cure.
Patients needs and preferences are in contrast with the available
evidence in the literature on the value of diagnostic tests for the
detection of asymptomatic metastases. This finding stresses the
point that patients need to be educated about the effectiveness of
follow-up examinations. It is now generally accepted that routine
surveillance for the early detection of breast cancer recurrence at
distant sites does not improve survival (GIVIO Investigators, 1994;
Rosselli et al, 1994; Joseph et al, 1998; Palli et al, 1999). The fact
that patients expected to have more chance of survival by
performing more tests and detect metastases at an early stage
means that they lack information on the primary goals of follow-
up. Also, the chance of recurrence is decreasing by the widespread
use of adjuvant therapy and there is no need for lifetime follow-up.
This survey reveals shortcomings in our patient education at that
time. Patients were not counselled by a breast-care nurse and there
was no structured written information on these topics available. A
number of innovations have been introduced in our care during
the last years and it would be interesting to see if a more proper
education programme will have influence on the expected benefits
of routine follow-up care in breast cancer patients.
Patient’s needs and preferences are supposed to be related to the
follow-up care that patients actually receive. The follow-up
programme was based on the guidelines of the Dutch Association
of Comprehensive Cancer Centers of the nineties (Vademecum
Oncologie, 1992), which is merely based on expert opinion than on
evidence on how often patients should be reviewed to fulfill the
goals of follow-up (detection of recurrence, detection of side effects
of treatment, and psychosocial support).
Contrary to the findings of other studies (Jefford and Tattersall,
2002), not all patients needed all types of information during
routine follow-up, after a diagnosis of breast cancer. We found that
only one patient desired all the information about her cancer and
half of the patients rated less than 50% of the information as very
important, suggesting that need for information decreases over
time after a diagnosis of breast cancer. Indeed, Mesters et al (2001)
also reported that the group of patients expressing no need for
information increased 1 year after treatment. In our study, the
median time from surgical treatment to follow-up was 3 years and
ranged from 2 to 4 years, which may explain the seemingly further
decrease of need for information. It would be interesting to do
research on how the needs and preferences of patients change over
time when the interval to their primary treatment is increasing.
Younger age was related to a greater need for information
during follow-up. The relationship between age and information
need among patients with a recent diagnosis of cancer was
reported earlier (Cassileth et al, 1980; Wallberg et al, 2000). Less
satisfaction with interpersonal aspects (interpersonal manner and
time spent with physician) and a higher score on the HADS-
anxiety scale were also related to higher information needs. Other
studies also found that the need for information after a diagnosis
of cancer was positively related to an elevated level of anxiety
(Jefford and Tattersall, 2002). However, one cannot conclude from
these findings that information provision will reduce anxiety
levels.
For patients newly diagnosed with cancer, the priority informa-
tion needs are focused on short-term effects and appear to be:
details about available treatment regimes, side effects of treatment,
extent of the disease, likelihood of cure and prognosis, self-care,
and return to a normal lifestyle (Mills and Sullivan, 1999).
Comparing these needs to those of the patients in our study, we see
more information needs focused on long-term effects of a
diagnosis of breast cancer.
Higher scores on the HADS-anxiety and -depression scale
were related to stronger preferences for additional investiga-
tions. Receiving adjuvant hormonal or radiotherapy was related
to a preferred, more intensive, follow-up schedule. This can
be ascribed to the fact that, according to national guidelines,
patients with a worse prognosis more often receive adjuvant
therapy.
As in other studies (Morris et al, 1992), patients preferred
follow-up to be performed by a hospital doctor. This may be
explained by the fact that at the time of this study, a hospital
doctor performed follow-up twice a year (due to the length of
follow-up), making this the familiar situation. Results from other
studies show that patients who have really experienced follow-up
performed by a breast-care nurse (Earnshaw and Stephenson,
1997) or by their general practitioner are very satisfied with it
(Grunfeld et al, 1999).
Overall, the HADS-anxiety scores (mean: 5.0 vs 5.1) and the
HADS-depression scores (mean: 2.7 vs 3.4) were comparable to
Dutch norm scores. In literature, high HADS scores are found
among women with a recent diagnosis of breast cancer. For
example, Osborne reported a prevalence of 24% of women, with
scores of 11 or greater, being most likely to have had anxiety or
depressive disorders based on DSM-IV criteria (Osborne et al,
2003). Others showed that after a diagnosis of breast cancer,
psychological morbidity tended to decrease over a 12-month
period (McArdle et al, 1996). After a year, the prevalence of anxiety
and depression was not increased in long-term survivors of breast
cancer who are apparently free of disease (Ellman and Thomas,
1995).
Regarding follow-up, women tend to vary in their appreciation
of different aspects of follow-up (Adewuyi-Dalton et al, 1998;
Koinberg et al, 2001). When introducing alternative follow-up
schedules, individual patients’ information needs and preferences
should be identified early and incorporated into this routine
follow-up care, to target resources and maximise the likelihood
that positive patient outcomes will result.
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